Eliquis Tablet, Film Coated
Product Images NDC 71610-811

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Eliquis (NDC 71610-811). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 811 83)

ELIQUIS 2.5 mg film-coated tablets label for apixaban, displaying NDC 71610-811-83. The label indicates a package size of 3600 tablets, storage instructions (20-25 degrees Celsius), and manufacturer information for Bristol-Myers Squibb Company in Princeton, NJ, with packaging by Aphena Pharma Solutions in Cookeville, TN. Additional details include lot and batch numbers, and handling precautions.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Apixaban Chemical Structure (Apixaban Struct)

Chemical structure of apixaban, the active ingredient in ELIQUIS, a 2.5 mg oral film-coated tablet by Aphena Pharma Solutions - Tennessee, LLC. The structure shows the molecular arrangement of atoms forming apixaban.*

FDA Label Image

Aristotle Forest Plot (Eliquis Clin Forest Fig5)

A forest plot comparing the rates of events per year between Apixaban and Warfarin across various patient subgroups including age, sex, weight, prior stroke or TIA, diabetes status, CHADS2 score, creatinine clearance, geographic region, and aspirin use. The plot shows hazard ratios with 95% confidence intervals, visualizing Apixaban's effectiveness relative to Warfarin in these subpopulations.*

FDA Label Image

Aristotle Major Bleeding Forest Plot (Eliquis Forest Fig1)

A forest plot comparing hazard ratios for apixaban versus warfarin across various patient subgroups. The plot shows point estimates and 95% confidence intervals for subgroups defined by prior warfarin status, age, sex, weight, prior stroke or TIA, diabetes mellitus, CHADS2 score, creatinine clearance, geographic region, and aspirin use at randomization. The x-axis represents hazard ratios indicating relative benefit between apixaban and warfarin.*

FDA Label Image

Aristotle Kaplan-meier Curve (Eliquis Km Fig4)

A line graph depicting the proportion of subjects with stroke or systemic embolism over 36 months comparing ELIQUIS and Warfarin. The x-axis represents time in months, and the y-axis represents the proportion of subjects. The graph includes a table showing the number of subjects at risk for each treatment group at various time points. Statistical data such as p-value and hazard ratio are also displayed.*

FDA Label Image

Effect Of Coadministered Drugs On Pharmacokinetics Of Apixaban (Eliquis Pkplot Drugs Fig2)

A pharmacokinetic chart showing fold change and 90% confidence intervals for the effect of combined P-gp and strong CYP3A4 inhibitors and inducers on apixaban exposure. The chart displays Cmax and AUC values for interacting drugs such as ketoconazole, clarithromycin, diltiazem, naproxen, and rifampin, relative to a reference value.*

FDA Label Image

O:\e-submissions\pbo\products\eliquis 202155\08. Pas Esrd Dosing\01. Orig Submission\source\eliquis-pkplot-pop-fig3.jpg (Eliquis Pkplot Pop Fig3)

A pharmacokinetic chart showing fold change and 90% confidence intervals for apixaban (Eliquis) in various populations, comparing Cmax and AUC values relative to reference groups. Populations include renal impairment, age, body weight, and hepatic impairment, with dosing recommendations noted for each group, mostly indicating no dose adjustment.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.